Apex Biotechnology (TPE:1733) Total Liabilities : NT$617 Mil (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Apex Biotechnology Total Liabilities?

Apex Biotechnology's Total Liabilities for the quarter that ended in Mar. 2024 was NT$617 Mil.

Apex Biotechnology's quarterly Total Liabilities increased from Sep. 2023 (NT$477.14 Mil) to Dec. 2023 (NT$500.07 Mil) and increased from Dec. 2023 (NT$500.07 Mil) to Mar. 2024 (NT$616.63 Mil).

Apex Biotechnology's annual Total Liabilities declined from Dec. 2021 (NT$916.91 Mil) to Dec. 2022 (NT$696.81 Mil) and declined from Dec. 2022 (NT$696.81 Mil) to Dec. 2023 (NT$500.07 Mil).

Apex Biotechnology Total Liabilities Historical Data

The historical data trend for Apex Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apex Biotechnology Total Liabilities Chart

Apex Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,137.37

1,005.28

916.91

696.81

500.07

Apex Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															707.40	651.44	477.14	500.07	616.63

Apex Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Apex Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	383.354	+	(116.196	+	0.52000000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	500

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2297.004	-	1796.934
	=	500

Apex Biotechnology's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	498.708	+	(115.83	+	2.087
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	617

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	2333.93	-	1717.305
	=	617

Apex Biotechnology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Apex Biotechnology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Apex Biotechnology (TPE:1733) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apex Biotechnology Corp (TPE:1733) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu, TWN, 30078

Website

https://www.apexbio.com

Apex Biotechnology Corp engages mainly in research, development, production, manufacturing and selling of biochemical testing instruments and its detection strips, and trade of products and components relevant to the core business. The company develops and markets biosensor-based blood glucose monitoring systems. The company manufactures non-invasive diagnostic technologies, IT-based telehealth care and molecular diagnostic and traditional Chinese medicine. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, HemoSmart GOLD hemoglobin screening system among others.

Apex Biotechnology (TPE:1733) Headlines

No Headlines